Events and Presentations

Date	Title
December 14, 2020	Investor presentation – December 14, 2020 2.4 MB
December 14, 2020	Complement R&D Day Presentation 4.9 MB
December 07, 2020	ASH – Crimson 1 Study: Phase 3 study to evaluate the efficacy and safety of subcutaneous marzeptacog alfa (activated) for on-demand treatment and control of bleeding episodes in subjects with hemophilia A or hemophilia B, with inhibitors 331.2 KB
November 24, 2020	Piper Sandler Virtual Healthcare Conference Presentation 1.9 MB
July 13, 2020	ISTH – Marzeptacog alfa (activated) population pharmacokinetics (PK): Simulations for dose selection in Phase 3 trials 2.1 MB
July 13, 2020	ISTH – Phase 1 study to evaluate the pharmacokinetics, pharmacodynamics, and safety of ascending doses of subcutaneous marzeptacog alfa (activated) in adult subjects with hemophilia 1 MB
June 19, 2020	WFH - Combination of a Novel Chimeric AAV Capsid and Potency Enhanced FIX Variant for Hemophilia B Gene Therapy 2 MB
June 15, 2020	WFH - Phase 2B Trial to Evaluate the Safety and Factor IX Levels of a Daily Subcutaneous Prophylaxis Treatment Regimen of Dalcinonacogalfa in Hemophilia B 2.1 MB